



# Outcomes of ureteroscopy for stone disease in anomalous kidneys: a systematic review

Lisa Lavan<sup>1</sup> · Thomas Herrmann<sup>2</sup> · Christopher Netsch<sup>3</sup> · Benedikt Becker<sup>3</sup> · Bhaskar K. Somani<sup>1,4</sup>

Received: 13 February 2019 / Accepted: 11 May 2019 / Published online: 17 May 2019  
© The Author(s) 2019

## Abstract

**Introduction** Treatment of stone disease in anomalous kidneys can be challenging. As ureteroscopy (URS) has advanced, the number of studies reporting on outcomes of URS for stone disease in anomalous kidneys has increased. Our objective was to perform a systematic review of the literature to evaluate the outcomes of URS for stone disease in this group of patients.

**Methods** A Cochrane style review was performed in accordance with the PRISMA guidelines using Medline, EMBASE, CINAHL, Cochrane Library, Scopus and individual urologic journals for all English language articles between inception and June 2018.

**Results** Fourteen papers (413 patients) with a mean age of 43 years and a male to female ratio of 285:128 were included. The underlying renal anomaly was horseshoe kidney ( $n=204$ ), ectopic kidney ( $n=117$ ), malrotation ( $n=86$ ), cross fused ectopia ( $n=2$ ) and others ( $n=2$ ). With a mean stone size of 16 mm (range 2–35 mm), the majority of stones were in the lower pole ( $n=143$ , 34.6%) or renal pelvis ( $n=128$ , 31.0%), with 18.9% ( $n=78$ ) having stones in multiple locations. Treatment modality included the use of flexible ureteroscope in 90% of patients and ureteral access sheath used in 11 studies. With a mean operative time of 61.3 min (range 14–185 min), the initial and final SFR was 76.6% ( $n=322$ ) and 82.3% ( $n=340$ ), respectively. The overall complication rate was 17.2% ( $n=71$ ), of which 14.8% were Clavien I/II and the remaining 2.4% were Clavien  $\geq$  III complications.

**Conclusion** Although ureteroscopy in patients with anomalous kidneys can be technically challenging, advancements in endourological techniques have made it a safe and effective procedure. In these patients the stone-free rates are good with a low risk of major complications.

**Keywords** Renal anomaly · Horseshoe kidney · Ectopic kidney · Malrotation · Pelvic · Ureteroscopy · Urolithiasis · RIRS

✉ Bhaskar K. Somani  
b.k.somani@soton.ac.uk; bhaskarsomani@yahoo.com

Lisa Lavan  
lisa.lavan@nhs.net

Thomas Herrmann  
thomas.herrmann@stgag.ch

Christopher Netsch  
c.netsch@asklepios.com

Benedikt Becker  
ben.becker@asklepios.com

<sup>1</sup> University Hospital Southampton NHS Trust, Southampton, UK

<sup>2</sup> Klinikdirektor Urologie Spital Thurgau AG, Chefarzt Urologie Kantonsspital Frauenfeld, Frauenfeld, Thurgau, Switzerland

<sup>3</sup> Department of Urology, Asklepios Hospital Barmbek, Rübentkamp 220, 22291 Hamburg, Germany

<sup>4</sup> University of Southampton, Southampton, UK

## Introduction

Anomalous kidneys arise from different abnormalities in the embryological development [1]. These may relate to abnormal ascent, fusion, rotation or a combination of these. Whilst the commonest renal anomaly is the horseshoe kidney (HSK) with an incidence of 1 in 400, ectopic kidneys (EK) are reported with an incidence of 1 in 3000, with the incidence of isolated malrotation (MR) less widely reported [1].

These anatomical anomalies not only lead to compromised renal drainage, but also increase the risk of urolithiasis [2–4]. Endourological management is challenging due to these abnormalities leading to difficulties accessing the stone [2]. Treatment such as shockwave lithotripsy (SWL) and percutaneous nephrolithotomy (PCNL) are well described in anomalous kidneys, but can be technically challenging,

with success rates often reported to be lower than those in normal kidneys [3–8].

Advances in technology and technique have allowed a broadening of indications for flexible ureterorenoscopy (FURS). The development of smaller calibre ureteroscopes with their increased deflection capability, along with holmium laser fibres and other adjuncts, make FURS an attractive treatment modality for challenging intrarenal anatomy [9].

Recently, the number of studies reporting on the outcomes of ureteroscopy (URS) in anomalous kidneys has increased. However, endoscopic access can be challenging, with complications and stone-free rates (SFR) that are variable across the reported studies. This article aims to review and summarise the efficacy and safety of FURS for urolithiasis in anomalous kidneys.

## Methods

### Search strategy and study selection

Our systematic review was performed according to Cochrane review guidelines and the preferred reporting items for systematic reviews and meta-analysis (PRISMA) standards [10]. A literature search was conducted using MEDLINE, EMBASE, CINAHL, Scopus, the Cochrane Library and individual urology journals for all English language articles. Search terms used included the following: ‘ureteroscopy’, ‘ureterorenoscopy’, ‘retrograde intrarenal

surgery’, ‘RIRS’, ‘URS’, ‘ureteroscopy’, ‘ureteroscopic management’, ‘urolithiasis’, ‘anomalous kidney’, ‘malrotation’, ‘horseshoe kidney’, ‘ectopic kidney’, ‘calculi’ and ‘stone’. The references of identified studies were examined to identify any further potential studies for inclusion. Boolean operators (AND, OR) were used to refine the search. The study period was from inception of databases to June 2018 (Fig. 1).

A cutoff of five patients was set to include studies from centres with minimum relevant endourological experience in managing stones in anomalous kidneys. All original studies were included and where more than one article was available, the study with the longest follow-up was included. Two reviewers (LL and BS) not involved in the original work identified all the studies and those that appeared to fit the inclusion criteria were included for full review. The studies were selected independently, and all discrepancies resolved by mutual consensus.

### Inclusion criteria

1. All English language articles reporting on the outcomes of ureteroscopic management of urolithiasis in anomalous kidneys.
2. Patients of all age groups.




Fig. 1 PRISMA flowchart of the included studies

## Exclusion criteria

1. Case reports, review articles and case series with less than five patients.
2. Simulation, animal and laboratory studies.
3. Studies with non-urolithiasis condition or use of treatments other than URS.

## Data extraction and analysis

Of the eligible studies, data were extracted for patient and stone demographics, previous endourological procedures, imaging modality used, operative technique, including laser fibre size and settings used, SFR including stone-free definition, need for further procedures, follow-up protocol and complications, using Clavien–Dindo classification [11]. Data was collated using Microsoft Excel (version 12.2.4). Quality of evidence was assessed, and bias was analysed using the GRADE assessment tool [12].

## Results

After initial identification and screening of 217 articles, 20 abstracts were further evaluated. Of these, on screening of abstracts and full paper, 14 full text articles were included in the final review (Fig. 1). In total, 413 patients with a mean age of 43 years (range 1–78 years) and a male to female ratio of 285:128 were included. The underlying renal anomaly was HSK ( $n = 204$ ), EK ( $n = 117$ ), MR ( $n = 86$ ), cross fused ectopia ( $n = 2$ ) and others ( $n = 4$ ). The majority of these

studies ( $n = 13$ ) were retrospective with just one prospective study [26] (Table 1).

The mean stone size reported from 12 studies was 16 mm (range 2–35 mm). In the majority of patients the stone location was in the lower pole ( $n = 143$ , 34.6%) or renal pelvis ( $n = 128$ , 31%), with 18.9% ( $n = 78$ ) having stones in multiple locations (Table 2). Pre-operative imaging included a combination of modalities [intravenous urogram (IVU), plain abdominal KUB XR (AXR), ultrasound scan (USS) or CT scan], although two studies used non-contrast computerised tomography (NCCT) as the only imaging modality [14, 24] (Table 3). A total of 126 (30.5%) patients had a history of previous endourological intervention [13–19, 22, 25] (Table 3).

While semirigid URS was used in 41 (10%) cases, FURS was used in 90% of cases. Of the reported studies, a pre-operative stent was reported in 26.4% (range 12.4–84.6%, 40/136 patients) [13–15, 24–26]. Placement of ureteral access sheath (UAS) was reported in 11 studies [13–19, 21, 22, 24, 25]. The success rates for UAS placement varied from 50 to 100% across studies (Table 4). Fragmentation device was reported in 13 studies, of which 12 used holmium laser lithotripsy for all of their patients. A range of fibre sizes and energy settings was reported. The mean operative time was 61.3 min (range 14–185 min). While six studies report a post-operative stent placement in all of their patients [13, 14, 19, 21, 22, 26], in the remaining studies this varied from 46.2 to 84% and was at the surgeon's discretion [15–17, 23–25]. The mean hospital stay across studies was 1.7 days (range 0.5–9 days) (Table 4).

With no universal definition of SFR between studies, their follow-up imaging also varied and sometimes even within

**Table 1** Patient demographics and case mix of the included studies

| References            | Study design  | Total patients | HSK | EK  | MR | Other | Mean age, years (range) | Male | Female |
|-----------------------|---------------|----------------|-----|-----|----|-------|-------------------------|------|--------|
| Weizer et al. [13]    | Retrospective | 8              | 4   | 4   | 0  | 0     | 50.6 (35–69)            | 6    | 2      |
| Molimard et al. [14]  | Retrospective | 17             | 17  | 0   | 0  | 0     | 34.7 (16–52)            | 14   | 3      |
| Atis et al. [15]      | Retrospective | 20             | 20  | 0   | 0  | 0     | 40.9 (NR)               | 12   | 8      |
| Bozkurt et al. [16]   | Retrospective | 26             | 0   | 26  | 0  | 0     | 41.1 (7–72)             | 19   | 7      |
| Oğuz et al. [17]      | Retrospective | 24             | 0   | 0   | 24 | 0     | 39.8 (1–71)             | 18   | 6      |
| Urgulu et al. [18]    | Retrospective | 25             | 3   | 11  | 4  | 5     | 39.4 (NR)               | 17   | 8      |
| Ding et al. [19]      | Retrospective | 16             | 16  | 0   | 0  | 0     | 42.9 (22–66)            | 13   | 3      |
| Blackburn et al. [20] | Retrospective | 20             | 20  | 0   | 0  | 0     | 48.1 (29–78)            | 13   | 7      |
| Gokce et al. [21]     | Retrospective | 23             | 23  | 0   | 0  | 0     | 42.5 (16–78)            | 18   | 5      |
| Bansal et al. [22]    | Retrospective | 9              | 9   | 0   | 0  | 0     | NR                      | 7    | 2      |
| Ergin et al. [23]     | Retrospective | 101            | 36  | 33  | 32 | 0     | 39.0 (1–72)             | 68   | 33     |
| Singh et al. [24]     | Retrospective | 25             | 5   | 14  | 5  | 1     | 38.28 (NR)              | 17   | 8      |
| Legemate et al. [25]  | Retrospective | 86             | 43  | 27  | 16 | 0     | 49.2 (NR)               | 57   | 29     |
| Astolfi et al. [26]   | Prospective   | 13             | 8   | 0   | 5  | 0     | 46.1 (NR)               | 6    | 7      |
| Total                 |               | 413            | 204 | 117 | 86 | 6     | 43.4                    | 285  | 128    |

HSK horseshoe kidney, EK ectopic kidney, MR malrotation

**Table 2** Stone size and location in the included studies

| References            | Stone size mean (mm)/[mm <sup>2</sup> ] | Stone size range (mm)/[mm <sup>2</sup> ] | Single stone | Multiple stones | Stone position, lower pole | Stone position, midpole | Stone position, upper pole | Stone position, renal pelvis | Stone position, mixed | Stone position, upper ureter |
|-----------------------|---|--|--------------|-----------------|----------------------------|-------------------------|----------------------------|------------------------------|-----------------------|------------------------------|
| Weizer et al. [13]    | 14                                      | 3–20                                     | 5            | 3               | 4                          | 0                       | 2                          | 5                            | (3)                   | 0                            |
| Molimard et al. [14]  | 16                                      | 7–35                                     | 7            | 10              | –                          | –                       | –                          | 7                            | 10                    | 0                            |
| Atis et al. [15]      | 17.8                                    | ±4.5                                     | 5            | 15              | 9                          | 7                       | 4                          | 5                            | (5)                   | 0                            |
| Bozkurt et al. [16]   | 17                                      | 10–28                                    | 21           | 5               | 7                          | 0                       | 0                          | 14                           | 5                     | 0                            |
| Oğuz et al. [17]      | 13.5                                    | 5–30                                     | 24           | 0               | 9                          | 3                       | 2                          | 10                           | 0                     | 0                            |
| Urgulu et al. [18]    | [194.7]                                 | [85–393]                                 | 19           | 6               | 14                         | 4                       | 7                          | 7                            | (6)                   | 0                            |
| Ding et al. [19]      | 29.8                                    | 17–42                                    | 4            | 12              | 1                          | 1                       | 0                          | 2                            | 12                    | 0                            |
| Blackburn et al. [20] | 8.4                                     | 2–25                                     | 17           | 3               | 10                         | NR                      | NR                         | NR                           | NR                    | 0                            |
| Gokce et al. [21]     | 17.1                                    | 6–25                                     | 14           | 9               | 6                          | 0                       | 0                          | 17                           | 0                     | 0                            |
| Bansal et al. [22]    | 15.4                                    | NR                                       | 6            | 3               | 12                         | 0                       | 0                          | 0                            | 0                     | 0                            |
| Ergin et al. [23]     | 16.1                                    | NR                                       | NR           | NR              | 35                         | 16                      | 14                         | 45                           | (9)                   | 0                            |
| Singh et al. [24]     | 14.7                                    | ±4.1 mm                                  | 15           | 10              | 11                         | 8                       | 5                          | 11                           | (12)                  | 2                            |
| Legemate et al. [25]  | [84]                                    | [4–117]                                  | 70           | 16              | 18                         | 3                       | 2                          | 3                            | 15                    | 13                           |
| Astolfi et al. [26]   | 12.2                                    | 6–22                                     | 12           | 1               | 7                          | 2                       | 0                          | 2                            | 1                     | 0                            |
| Total [mean]          | [16.0]                                  |  | 219          | 93              | 143                        | 44                      | 36                         | 128                          | 78                    | 15                           |

**Table 3** Data on pre-operative variables

| References            | Pre-operative imaging | Pre-operative urine MC and S | Peri-operative antibiotics | Pre-operative stent | Previous SWL | Previous PCNL | Previous open procedure | Previous URS | > 1 previous procedure |
|-----------------------|-----------------------|------------------------------|----------------------------|---------------------|--------------|---------------|-------------------------|--------------|------------------------|
| Weizer et al. [13]    | IVU or NCCT           | NR                           | NR                         | 1 (12.5%)           | 6            | 0             | 1                       | 0            | 1                      |
| Molimard et al. [14]  | NCCT                  | Yes                          | NR                         | 4 (23.5%)           | 8            | 4             | 2                       | 3            | NR                     |
| Atis et al. [15]      | AXR and IVU or US     | Yes                          | Yes                        | 0                   | 4            | 4             | 4                       | 0            | 4                      |
| Bozkurt et al. [16]   | NCCT or IVU           | Yes                          | NR                         | NR                  | 9            | 0             | 1                       | 0            | 0                      |
| Oğuz et al. [17]      | AXR, IVU, US or NCCT  | Yes                          | Yes                        | NR                  | 12           | 0             | 0                       | 4            | 0                      |
| Urgulu et al. [18]    | IVU and CT            | Yes                          | NR                         | NR                  | 7            | 2             | 2                       | 1            | NR                     |
| Ding et al. [19]      | AXR and IVU or NCCT   | NR                           | Yes                        | NR                  | 7            | 1             | 0                       | 0            | 1                      |
| Blackburn et al. [20] | NR                    | NR                           | NR                         | NR                  | NR           | NR            | NR                      | NR           | NR                     |
| Gokce et al. [21]     | AXR and USS or NNCT   | Yes                          | Yes                        | NR                  | NR           | NR            | NR                      | NR           | NR                     |
| Bansal et al. [22]    | AXR, IVU, USS or NCCT | NR                           | Yes                        | NR                  | 2            | 5             | 0                       | 0            | 0                      |
| Ergin et al. [23]     | IVU, USS or NCCT      | Yes                          | NR                         | NR                  | NR           | NR            | NR                      | NR           | NR                     |
| Singh et al. [24]     | CTU                   | Yes                          | NR                         | 5 (20%)             | NR           | NR            | NR                      | NR           | NR                     |
| Legemate et al. [25]  | AXR, IVU or NCCT      | Yes                          | Yes                        | 18 (24.7%)          | 20           | 12            | 0                       | 15           | NR                     |
| Astolfi et al. [26]   | AXR or NCCT           | NR                           | NR                         | 11 (84.6%)          | NR           | NR            | NR                      | NR           | NR                     |
| Total                 |                       |                              |                            | 40 (29.4%)          | 75 (59.2%)   | 28 (22.2%)    | 10 (7.9%)               | 23 (18.3%)   |                        |

AXR plain abdominal X-ray, IVU intravenous urogram, USS ultrasound scan, NCCT non-contrast computerised tomography, CTU computerised tomography urogram, NR not reported, SWL shockwave lithotripsy, PCNL percutaneous nephrolithotomy, URS ureteroscopy

each study. While ten studies did the post-operative imaging after 4 weeks [13–19, 21, 22, 24], one study did it after 3 months [26] and the remaining three did not mention the time interval for follow-up imaging [20, 23, 25] (Table 5).

The initial and final SFR was 76.6% ( $n = 322$ ) and 82.3% ( $n = 340$ ), respectively, with 18 patients needing ancillary treatment which was a mix of repeat URS or SWL or PCNL (Table 5). Three studies reported the demographics and outcomes of HSK, EK and MR individually [18, 23, 25] (Table 6).

Overall, 71 (17.2%) complications were reported of which 61 (14.8%) were Clavien–Dindo  $\leq$  II, and 10 (2.4%)

were Clavien–Dindo  $\geq$  III. The Clavien I/II complications included stent symptoms ( $n = 7$ ), haematuria ( $n = 15$ ), post-operative pyrexia ( $n = 21$ ) and confirmed urinary tract infection ( $n = 6$ ). Of the nine Clavien III complications, surgical intervention for ureteric colic accounted for seven of these and the remaining two interventions were not specified. The single Clavien IV complication occurred in one of the largest studies [25], where an obese patient with a large stone (262 mm [2]) and prolonged operating time (121 min) developed sepsis with acute renal failure. This patient was treated with percutaneous nephrostomy, antibiotics and intensive care support (ICU) (Tables 5, 7).

**Table 4** Intraoperative and post-operative data from included studies

| References            | Anaesthesia | Procedure  | Holmium laser | Fibre size ( $\mu\text{m}$ ) | Energy setting (J) | Energy setting (Hz) | Access sheath used | Post-operative stent | Mean operative time, min (range) | Length of stay, days (range) |
|-----------------------|-------------|--|---------------|------------------------------|--------------------|---------------------|--------------------|----------------------|----------------------------------|------------------------------|
| Weizer et al. [13]    | NR          | FURS   | Yes           | 200                          | 0.6–1.0            | 6–10                | 4 (50%)            | 8 (100%)             | 126 (90–185)                     | NR                           |
| Molimard et al. [14]  | GA          | FURS   | Yes           | 150 or 365                   | 0.8–1.2            | 8–12                | 17 (100%)          | 17 (100%)            | 92 (45–140)                      | 1.7 (1–3)                    |
| Atis et al. [15]      | GA          | SRU and FURS                                       | Yes           | 273                          | 0.6–1.0            | 5–10                | 20 (100%)          | 15 (75%)             | 40.5                             | 1.4                          |
| Bozkurt et al. [16]   | GA          | FURS   | Yes           | 200                          | 0.8                | 10                  | 0                  | 12 (46%)             | 52.1 (30–120)                    | 2.7 (1–9)                    |
| Oğuz et al. [17]      | GA          | SRU and FURS                                       | Yes           | 273                          | NR                 | NR                  | 20 (83%)           | 17 (71%)             | 48.7 (18–135)                    | 1.5 (1–5)                    |
| Urgulu et al. [18]    | GA          | FURS   | Yes           | 200 or 273                   | NR                 | NR                  | 18 (72%)           | NR                   | 48 (14–115)                      | NR                           |
| Ding et al. [19]      | Spinal      | SRU and FURS                                       | Yes           | 200                          | 0.8–1.2            | 10–15               | 16 (100%)          | 16 (100%)            | 92 (14–127)                      | 0.8 (0–3)                    |
| Blackburn et al. [20] | NR          | NR   | NR            | NR                           | NR                 | NR                  | NR                 | NR                   | NR                               | NR                           |
| Gokce et al. [21]     | GA          | FURS   | Yes           | NR                           | 0.8–1.2            | 8–12                | 23 (100%)          | 23 (100%)            | NR                               | 1.8 (1–3)                    |
| Bansal et al. [22]    | GA          | FURS   | Yes           | 200                          | 0.6–0.8            | 10–15               | 9 (100%)           | 9 (100%)             | 84.2                             | NR                           |
| Ergin et al. [23]     | GA          | SRU and FURS                                       | Yes           | 170 or 200                   | NR                 | NR                  | NR                 | 50 (50%)             | 47.1                             | 1.9                          |
| Singh et al. [24]     | GA          | FURS   | Yes           | 200 or 365                   | 0.5–1.0            | 10–15               | 25 (100%)          | 21 (84%)             | 74                               | 2.48                         |
| Legemate et al. [25]  | NR          | SRU alone 47.7%<br>FURS 32.6%<br>Combination 17.4% | 57%           | NR                           | NR                 | NR                  | 29 (71%)           | 71 (84%)             | 58 (30–120)                      | 1 (0.5–5)                    |
| Astolfi et al. [26]   | GA          | SRU and FURS                                       | Yes           | 200 or 273                   | NR                 | NR                  | NR                 | 13 (100%)            | NR                               | NR                           |

GA general anaesthetic, SRU semirigid ureteroscopy, FURS flexible ureteroscopy, NR not reported

**Table 5** Post-operative outcomes from included studies

| References            | Definition of success | Post-op imaging modality | Imaging time interval (weeks) | Overall success rate (%) | Success after single procedure | Auxiliary procedures required | Readmission | Complications Clavien I–II | Complications Clavien ≥ III |
|-----------------------|-----------------------|--------------------------|-------------------------------|--------------------------|--------------------------------|-------------------------------|-------------|----------------------------|-----------------------------|
| Weizer et al. [13]    | Stone free            | AXR and IVU or NCCT      | 4–12                          | 75.0                     | 75.0                           | 0                             | NR          | 0                          | 0                           |
| Molimard et al. [14]  | RF ≤ 3 mm             | AXR and USS or NCCT      | 4 - 6                         | 88.2                     | 53.0                           | 7 URS                         | 1           | 8                          | 0                           |
| Atis et al. [15]      | RF < 4 mm             | IVU and USS (NCCT if RF) | 4                             | 80.0                     | 70.0                           | 6 SWL                         | 0           | 5                          | 0                           |
| Bozkurt et al. [16]   | RF ≤ 2 mm             | NCCT                     | 4                             | 84.7                     | NR                             | NR                            | NR          | 3                          | 2                           |
| Oğuz et al. [17]      | RF ≤ 3 mm             | IVU and USS (NCCT if RF) | 4                             | 83.3                     | 75.0                           | 1 SWL<br>1 URS                | 1           | 11                         | 2                           |
| Urgulu et al. [18]    | Complete clearance    | NCCT                     | 4                             | 88.0                     | 64.0                           | 6 URS<br>3 SWL                | NR          | 3                          | 0                           |
| Ding et al. [19]      | Not defined           | AXR and USS              | 4                             | 87.5                     | 62.5                           | 6 URS                         | NR          | 3                          | 0                           |
| Blackburn et al. [20] | RF < 4 mm             | AXR or CT                | NR                            | 84.0                     | NR                             | NR                            | NR          | NR                         | NR                          |
| Gokce et al. [21]     | RF < 3 mm             | AXR and/or USS/NCCT      | 2 - 6                         | 73.9                     | NR                             | NR                            | 0           | 4                          | 0                           |
| Bansal et al. [22]    | RF ≤ 4 mm             | AXR and USS or NCCT      | 4                             | 88.9                     | 67.7                           | 3 URS                         | 1           | 4                          | 0                           |
| Ergin et al. [23]     | RF < 3 mm             | NR                       | NR                            | 76.9                     | NR                             | 8 URS                         | NR          | 12                         | 2                           |
| Singh et al. [24]     | RF < 2 mm             | AXR and USS              | 4                             | 88.0                     | 72.0                           | 3 PCNL                        | NR          | 5                          | 1                           |
| Legemate et al. [25]  | RF ≤ 1 mm             | AXR and USS or NCCT      | NR                            | 58.3                     | NR                             | 15                            | 12          | 2                          | 3                           |
| Astolfi et al. [26]   | RF < 2 mm             | AXR or NCCT              | 12                            | 75.0                     | NR                             | NR                            | 0           | 1                          | 0                           |
| Overall               |                       |                          |                               | 82.3%<br>(n = 340)       | 76.6%<br>(n = 322)             | 18                            | 15          | 61 (14.8%)                 | 10 (2.4%)                   |

RF residual fragments, AXR plain abdominal X-ray, IVU intravenous urogram, USS ultrasound scan, NCCT non-contrast computed tomogram, URS ureteroscopy, SWL shockwave lithotripsy, PCNL percutaneous nephrolithotomy

## Quality assessment of the included studies

Of the 14 studies included, there was only one prospective study [26], with all others based on retrospective observational case series. The overall quality of evidence was graded as ‘very low’ and risk of bias ‘very high’ as detailed in Fig. 2.

## Discussion

### Meaning of the study

The incidence of anomalous kidneys is relatively low with mostly small retrospective studies reporting on the outcomes of surgery for urolithiasis in these patients. However, in

**Table 6** Studies reporting on outcomes for individual data for HSK, EK and MR

|                      |                     | Mean stone burden [range]   | Percentage of lower pole stones (%) | Success after single procedure | Overall success (%) |
|----------------------|---------------------|---|-------------------------------------|--------------------------------|---------------------|
| Urgulu et al. [18]   | HSK ( <i>n</i> =3)  | 253 mm <sup>2</sup> ± 103.7   | 50.0                                | 66.7%                          | 66.7                |
|                      | EK ( <i>n</i> =13)  | 237.7 mm <sup>2</sup> ± 94.4 (lumbar)<br>168.8 mm <sup>2</sup> ± 101.7 (pelvic) | 57.1<br>33.3                        | 61.5%                          | 100                 |
|                      | MR ( <i>n</i> =4)   | 201.3 mm <sup>2</sup> ± 109.5   | 75.0                                | 100%                           | 100                 |
| Ergin et al. [23]    | HSK ( <i>n</i> =36) | 17.8 mm ± 4.5   | 30.6                                | NR                             | 72.2                |
|                      | EK ( <i>n</i> =33)  | 17.0 mm ± 5.1   | 36.4                                | NR                             | 83.6                |
|                      | MR ( <i>n</i> =32)  | 13.4 mm ± 3.7   | 37.5                                | NR                             | 75.0                |
| Legemate et al. [25] | HSK ( <i>n</i> =23) | 70 mm <sup>2</sup> [46–134]   | 52.1                                | NR                             | 77.3                |
|                      | EK ( <i>n</i> =10)  | 120 mm <sup>2</sup> [79–263]  | 30.0                                | NR                             | 20.0                |
|                      | MR ( <i>n</i> =8)   | 62 mm <sup>2</sup> [0–148]  | 37.5                                | NR                             | 71.4                |

HSK horseshoe kidney, EK ectopic kidney, MR malrotation

**Table 7** Complications graded as per Clavien–Dindo classification

| References            | Clavien I–II  | Clavien ≥ III   |
|-----------------------|---|---|
| Weizer et al. [13]    | None  | None  |
| Molimard et al. [14]  | Stent symptoms <i>n</i> =6<br>Haematuria <i>n</i> =1<br>Pyelonephritis <i>n</i> =1                          | None  |
| Atis et al. [15]      | Post-operative pyrexia <i>n</i> =3<br>Haematuria <i>n</i> =2  | None  |
| Bozkurt et al. [16]   | Post-operative pyrexia <i>n</i> =1<br>Haematuria <i>n</i> =1<br>Urinary tract infection <i>n</i> =1         | Ureteric colic requiring JJ stent <i>n</i> =2   |
| Oğuz et al. [17]      | Post-operative pyrexia <i>n</i> =2<br>Ureteric colic (conservative management) <i>n</i> =9                  | Ureteric colic requiring surgical intervention <i>n</i> =2  |
| Urgulu et al. [18]    | Urosepsis <i>n</i> =1<br>Pyelonephritis <i>n</i> =1<br>Ureteric colic (conservative management) <i>n</i> =1 | None  |
| Ding et al. [19]      | Post-operative pyrexia <i>n</i> =3  | None  |
| Blackburn et al. [20] | Complications not reported  | Complications not reported  |
| Gokce et al. [21]     | Haematuria <i>n</i> =3<br>Post-operative pyrexia <i>n</i> =1  | None  |
| Bansal et al. [22]    | Post-operative pyrexia <i>n</i> =2<br>Stent symptoms <i>n</i> =1<br>Pyelonephritis <i>n</i> =1              | None  |
| Ergin et al. [23]     | Haematuria <i>n</i> =7<br>Post-operative pyrexia <i>n</i> =5  | Ureteric colic requiring JJ stent <i>n</i> =2   |
| Singh et al. [24]     | Post-operative pyrexia <i>n</i> =3<br>Urinary tract infection <i>n</i> =2                                   | Ureteric colic requiring JJ stent <i>n</i> =1   |
| Legemate et al. [25]  | Post-operative pyrexia <i>n</i> =1<br>Urosepsis <i>n</i> =1   | IIIa not defined <i>n</i> =1<br>IIIb not defined <i>n</i> =1<br>IVa Urosepsis requiring nephrostomy and ITU support <i>n</i> =1 |
| Astolfi et al. [26]   | Haematuria <i>n</i> =1  | None  |

experienced hands ureteroscopy can offer good SFR with a low risk of major (Clavien ≥ III) complications even for large stones. It seems that over the last decade, there have been more studies reporting on the outcomes of FURS in this setting.

### Comparison of studies reporting on FURS for renal anomalies

Weizer et al. [13] reported the first series on ureteroscopic management of renal calculi in eight patients with



| Ureteroscopy for stone disease in anomalous kidneys |                       |              |               |              |              | Certainty |
|---|-----------------------|--------------|---------------|--------------|--------------|-----------|
| Certainty assessment                                |                       |              |               |              |              |           |
| No of studies                                       | Study design          | Risk of bias | Inconsistency | Indirectness | Imprecision  |           |
| 14  | Observational studies | Very serious | Not serious   | Very serious | Very serious | Very Low  |

**Fig. 2** Risk of bias analysis

anomalous kidneys (four HSK, four EK) with stones up to 2 cm. They report the use of UAS to straighten the tortuous ureter, relocation of stone to a more favourable location and extraction of fragments leading to an overall success rate of 75% with none of the patient requiring auxiliary treatment.

Molimard et al. [14] reviewed the outcomes of FURS and holmium lasertripsy in 17 patients with horseshoe kidneys. They used UAS in all patients with automatic flow irrigation at 100 cm H<sub>2</sub>O to improve visualisation. While the laser settings varied upon clinical situations, stone repositioning and extraction was used for clearance. They also advised patients on force fluid intake post-operatively to facilitate passage of small fragments. However, staged FURS was needed in larger stones and those in difficult locations, with an overall success rate of 88.2%.

Atis et al. [15] described FURS in 20 patients with horseshoe kidneys. They performed a semirigid URS in all cases to initially dilate the ureter before placement of a UAS. They recommend stone relocation where possible and to use dusting setting (high frequency, low energy) for stone treatment. Failure was significantly higher in the lower pole and larger stones.

Bozkurt et al. [16] investigated the outcomes in 26 patients with pelvic ectopic kidneys. Stone relocation and dusting method of stone treatment was used; however, a UAS was not used due to short tortuous ureter. Although the treatment was successful in 84.7%, it failed in patients with unfavourable infundibulopelvic anatomy.

Oğuz et al. [17] used FURS for treating kidney stones in 24 patients with isolated anomaly of kidney rotation, excluding HSK and EK. They used semirigid URS to passively dilate the ureter and placed a UAS in 83% of patients, with an initial and final SFR of 75% and 83.3%, respectively.

Urgulu et al. [18] used FURS for stone disease in 25 patients with anomalous kidneys, including 1 patient with cross fused ectopia. They suggest the use of paediatric 9.5–11.5 F UAS in pelvic kidneys to overcome the difficulties of short tortuous ureters. The size of laser fibre and energy settings were determined intra-operatively according to stone size, location and composition.

Ding et al. [19] reviewed the efficacy of FURS in 16 patients with HSK. Semirigid URS and UAS were used in all patients. Stone relocation was seen to increase the SFR as well as protecting the ureteroscope by minimising the

duration of scope deflection. With six patients needing a repeat FURS, the initial and final SFR was 62.5% and 87.5%, respectively.

Gokce et al. [20] compared the outcomes of SWL and FURS for treatment of stone disease in 67 patients with HSK, with similar patient and stone demographics between the groups. They recommend placing the patients in a slight Trendelenburg position to encourage stones to fall into upper calyces. They also used UAS, repositioned lower pole stones, used automatic flow irrigation at 100 cm H<sub>2</sub>O to improve visualisation and placed a ureteric stent as well as a urethral catheter in all patients to maximise drainage post-operatively. The SFR rate was significantly higher ( $p=0.039$ ) in the FURS group (73.9%) compared to the SWL group (47.7%) with no significant difference in complication rates between the groups.

Bansal et al. [22] treated nine patients (12 renal units) with HSK and lower calyceal stones using FURS. They used UAS for all patients to optimise vision, keep a low intrarenal pressure and extract fragments. In cases where UAS placement was not possible, patients were stented and booked for a second planned procedure. With a stone dusting laser setting, the initial and final SFR was 67.7% and 88.7%, respectively.

Ergin et al. [23] reported on 101 patients who underwent surgery for urolithiasis in anomalous kidneys over a 10-year period. Surgical techniques included FURS for stones less than 2 cm and PCNL for stones greater than 2 cm, or laparoscopic pyelolithotomy for large stones in ectopic kidneys. The overall SFR for HSK in the FURS group was 72.2% compared to 90% in the PCNL group; however, 14 patients in the PCNL group required a second procedure. In the EK group, FURS was compared to laparoscopic pyelolithotomy, although all stones in the laparoscopic pyelolithotomy group were in the renal pelvis ( $n=9$ ). The SFR rate for EK was 83.6% and 100% for FURS and laparoscopic pyelolithotomy, respectively. Finally, SFR for isolated rotational anomalies for FURS and PCNL was 75% and 83.3%, respectively. The overall SFR for FURS in all renal anomalies combined was 76.9%.

Singh et al. [24] presented outcomes of FURS in 25 patients with various renal anomalies and stones < 2 cm. UAS and stone relocation to a favourable position was used in all patients. Laser settings were adjusted with dusting setting preferred for stone treatment. Patients were given an alpha blocker post-operatively and encouraged to increase their fluid intake to improve stone passage.

Legemate et al. [25] reviewed data from the Clinical Research Office of the Endourological Society (CROES) URS Global Study and, of the 11,885 patients included, 86 patients were identified with anomalous kidneys that underwent URS for both renal and ureteric stones. The SFR for patients with and without pre-operative stent was 67% and

78%, respectively, and with and without UAS was 66% and 50%, respectively. Although the mean stone burden was highest in the EK group (120 mm<sup>2</sup>), the SFR for HSK, MR and EK groups was 77%, 71% and 20%, respectively. The SFR decreased in all three groups for patients in case the stone burdens were greater than 80 mm<sup>2</sup>.

Astolfi et al. [26] collected prospective data on patients with anomalous kidneys undergoing FURS over a 6-year period and reported outcomes for 13 patients with an SFR of 75%. Semirigid ureteroscopy was performed initially and UAS use was preferred. Laser settings were adjusted according to stone location and composition with nitinol baskets used to relocate stones from unfavourable positions and to remove fragments.

The anatomical variations of anomalous kidneys can lead to difficulties in either localising or accessing stones for treatment and therefore a higher complication rate may be expected compared to surgery for stones in normally formed kidneys [27]. Bas et al. [28] retrospectively analysed data on 1395 patients undergoing FURS for renal or proximal ureteric calculi and attempted to determine predictive factors affecting complication rates. On multivariate analysis, the only significant predictive factor was the presence of congenital renal abnormalities.

The overall complication rate from the included studies was 17.2%. Out of these complications, only 2.4% were Clavien > III complications most of which related to re-intervention for ureteric colic. There was one Clavien IVa complication where a patient with urosepsis and acute renal failure received a nephrostomy and was transferred to the intensive care unit (ICU).

### Tips and practical stepwise guidance for management from the included studies

Based on the included studies, there were certain tips and recommendations for ureteroscopy for stone disease in anomalous kidneys (Fig. 3). In a stepwise manner this included:

1. Performing a semirigid URS prior to FURS to passively dilate the ureter.
2. Using a UAS if the ureteric anatomy allowed it and choosing a smaller length in pelvic kidneys. In EK, it should be adjusted to mid to lower ureter, or in a position such that the scope can flex in the pelvicalyceal system.
3. Relocation of stones from an unfavourable to a more favourable position.
4. Adjusting laser setting according to stone composition, but dusting seemed to be the preferred mode of stone treatment.
5. Fragment retrieval and stone clearance to increase the SFR.




Fig. 3 Tips and practical guidance for management

### Comparison of URS with PCNL and SWL in management of stones in anomalous kidneys

The anatomical variation of anomalous kidneys presents technical challenges to access stones for treatment irrespective of the surgical technique undertaken [29].

Whilst SWL has the advantage of being non-invasive and avoids the need for general anaesthesia, stone localisation can be difficult due to the overlying bony structures or due to interposed bowel gas. The skin to stone distance is often increased and, even if SWL was successful in fragmenting the stone, impaired drainage can hinder the passage of the fragments, resulting in reduced SFR [27].

Ray et al. [6] reviewed the data of 41 patients with HSK undergoing SWL for renal stones. The success rate defined as being stone free or asymptomatic with residual fragments < 4 mm after single treatment was only 25%, increasing to 63.6% with additional treatments. They observed very little clinical benefit of offering more than two SWL sessions and multivariate analysis found stone burden, stone position and patient body mass index to be prognostic for SWL success. Sheir et al. [7] reported on their experience of SWL in 198 patients who were treated for a mean stone size of 13.54 mm ( $\pm$  5.49). The overall SFR was 72.2% with 3.2% of patients who developed a steinstrasse. Tunc et al. [8] assessed the outcomes of 150 patients with anomalous kidneys and reported an overall SFR of 68% at 3 months. Stone size drove the success rate with SFR of 34% and 92% for stones > 30 mm and < 10 mm in size, respectively.

PCNL offered higher stone clearance rates compared to SWL, but with a higher risk of associated complications. Due to the anatomical variations and abnormal relationship to the adjacent organs (especially bowel), there was an increased risk of iatrogenic injury during percutaneous access in PCNL, and access tracts were often longer.

Abnormal vasculature was also common that must be considered in pre-operative planning [27]. Symons et al. [4] reviewed the 15-year outcomes of all patients who underwent surgical treatment for HSK. Of the 55 patients identified, the majority (85.5%) underwent PCNL, with an SFR of 77% after a single procedure. Tepeler et al. [3] analysed factors affecting outcomes of PCNL in 53 patients with HSK. For a mean stone size of 28.4 mm, the initial and final SFR was 66.7% and 90.7%, respectively. While auxiliary treatments increased SFR, the only factor affecting success rates on multivariate analysis was stone multiplicity.

### Strengths, limitations and areas of future research

This systematic review comprehensively summarises the evidence for the role of URS in the setting of anomalous kidneys. Apart from the outcomes, it looks at tips and practical stepwise guidance provided from the included studies. Furthermore, the results can potentially set a benchmark for patient counselling and future research. The quality of included studies was poor with a high risk of bias and based mostly on small retrospective series; however, given the rarity of this condition, our review provides valuable insight, helps to condense the literature and might offer pitfalls and treatment strategies to endourologists. Although the reported complications in anomalous kidneys were higher, the rates of major complications were not different compared to URS in anatomically normal kidneys [30]. Future studies should also look at the cost comparison of the different treatment modalities [31–33]. A lack of standardised methods of data collection and reporting made it difficult to compare or combine the outcomes [34]. Retrograde intrarenal surgery is now being done for complex patients including those with morbid obesity, pregnancy and paediatric patients [35–37]. Improved training, flexible ureteroscopy technology and advances in laser have led to this procedure being successful in those with anomalous kidneys [38–40].

Patients with stone disease in anomalous kidneys need individualised management and probably should involve an interdisciplinary treatment with interventional radiology colleagues with interventions carried out in high volume endourology centres. Although randomised trials between treatment modalities would be difficult given the rarity of this condition, perhaps large prospective multi-centric studies with long-term follow-up and standardised references would be able to provide with high-quality insightful data.

### Conclusion

Although URS in patients with anomalous kidneys can be technically challenging, advancements in endourological techniques have made it a safe and effective procedure. In

these patients, the stone-free rates are good with a low risk of major complications.

**Author contributions** Protocol/project development—LL, BKS. Data collection or management—LL, BKS. Data analysis—LL. Manuscript writing/editing—LL, TH, CN, BB, BKS.

**Funding** No funding was received for this work.

### Compliance with ethical standards

**Conflict of interest** The authors declare that there is no conflict of interest from any of the co-authors.

**Ethical approval** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

**Informed consent** Informed consent was obtained from all individual participants/parents included in the study.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

### References

- Wein AJ, Kavoussi LR, Campbell MF (2015) Campbell-Walsh Urology, 11th edn. Elsevier Saunders, Philadelphia, PA
- Raj GV, Auge BK, Assimos D et al (2004) Metabolic abnormalities associated with renal calculi in patients with horseshoe kidney. *J Endourol* 18:157–161
- Tepeler A, Sehgal PD, Akman T et al (2014) Factors affecting outcomes of percutaneous nephrolithotomy in horseshoe kidneys. *Urology* 84(6):1290–1294
- Symons SJ, Ramachandran A, Kurien A et al (2008) Urolithiasis in the horseshoe kidney: a Single-centre experience. *BJU Int* 102(11):1676–1680
- Viola D, Anagnostou T, Thompson TJ et al (2007) Sixteen years of experience with stone management in horseshoe kidneys. *Urol Int* 78(3):214–218
- Ray AA, Ghiculete D, Honey RJD'A et al (2011) Shockwave lithotripsy in patients with horseshoe kidneys: determinants of success. *J Endourol* 25(3):487–493
- Sheir KZ, Madbouly K, Elsobky E et al (2003) Extracorporeal shockwave lithotripsy in anomalous kidneys: 11 year experience with two second-generation lithotriptors. *Urology* 62(1):10–15
- Tunc L, Tokgoz H, Tan MO et al (2004) Stones in anomalous kidneys: results of treatment by shockwave lithotripsy in 150 patients. *Int J Urol* 11(10):831–836
- Guisti G, Proietti S, Peshechera R et al (2015) Sky is the limit for ureteroscopy: extending the indications and special circumstances. *World J Urol* 33:257–273
- Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses

- of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 339:b2700
11. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 240:205–213
  12. Schünemann H, Brożek J, Guyatt G, et al (2013). GRADE handbook for grading quality of evidence and strength of recommendations. <http://guidelinedevelopment.org/handbook>. Accessed 21 Jan 2019
  13. Weizer AZ, Spinghart PW, Ekeruo WO et al (2005) Ureteroscopic management of renal calculi in anomalous kidneys. *Urology* 65(2):265–269
  14. Molimard B, Al-Qahtani S, Laknichi A et al (2010) Flexible ureterorenoscopy with holmium laser in horseshoe kidneys. *Urology* 76(6):1334–1337
  15. Atis G, Resorlu B, Gurbuz C et al (2013) Retrograde Intrarenal surgery in patients with horseshoe kidneys. *Urolithiasis* 41:79–83
  16. Bozkurt OF, Tepeler A, Sninsky B et al (2014) Flexible ureterorenoscopy for the treatment of kidney stone within pelvic ectopic kidney. *Urology* 84(6):1285–1289
  17. Oğuz U, Balci M, Atis G et al (2014) Retrograde intrarenal surgery in patients with isolated anomaly of kidney rotation. *Urolithiasis* 42:141–147
  18. Urgulu IM, Akman T, Binbay M et al (2015) Outcomes of retrograde flexible ureteroscopy and laser lithotripsy for stone disease in patients with anomalous kidneys. *Urolithiasis* 43:77–82
  19. Ding J, Huang Y, Gu S et al (2014) Flexible ureteroscopic management of horseshoe kidney renal calculi. *Int Braz J Urol* 41:683–689
  20. Blackburne AT, Rivera ME, Gettman MT et al (2016) Endoscopic management of urolithiasis in the horseshoe kidney. *Urology* 90:45–49
  21. Gokce MI, Tokatli Z, Suer E et al (2016) Comparison of shock-wave lithotripsy (SWL) and retrograde intrarenal surgery (RIRS) for treatment of stone disease in horseshoe kidney patients. *Int Braz J Urol* 42:96–100
  22. Bansal P, Bansal N, Sehgal A et al (2016) Flexible ureteroscopy for lower calyceal stones in a horseshoe kidney—is it the new treatment of choice? *Afr J Urol* 22:199–201
  23. Ergin G, Kirac M, Unsal A et al (2017) Surgical management of urinary stones with abnormal kidney anatomy. *KJMS* 33:207–211
  24. Singh AG, Chhabra JS, Sabnis R et al (2017) Role of flexible ureterorenoscopy in management of renal calculi in anomalous kidneys: single-center experience. *World J Urol* 35:319–324
  25. Legemate JD, Baseskioglu B, Dobruch J et al (2017) Ureteroscopic urinary stone treatment among patients with renal anomalies: patients characteristics and treatment outcomes. *Urology* 110:56–62
  26. Astolfi RH, Freschi G, Berti FF et al (2017) Flexible ureterorenoscopy in position or fusion anomaly: is it feasible? *Rev Assoc Med Bras* 63(8):685–688
  27. Ganpule AP, Desai MR (2011) Urolithiasis in kidneys with abnormal lie, rotation or form. *Curr Opin Urol* 21:145–153
  28. Bas O, Tuygun C, Dede O et al (2017) Factors affecting complication rates of retrograde flexible ureterorenoscopy: analysis of 1571 procedures—a single-centre experience. *World J Urol* 35(5):819–826
  29. Pawar A, Thongprayoon C, Cheungpasitporn W et al (2018) Incidence and characteristics of kidneys stones in patients with horseshoe kidney: a systematic review and meta-analysis. *Urol Ann* 10(1):87–93
  30. Somani BK, Giusti G, Sun Y et al (2017) Complications associated with ureteroscopy (URS) related to treatment of urolithiasis: the Clinical Office of Endourological Society URS Global Study. *World J Urol* 35(4):675–681
  31. Geraghty R, Jones P, Herrmann T et al (2018) Ureteroscopy seems to be clinically and financially more cost effective than shock wave lithotripsy for stone treatment: systematic review and meta-analysis. *World J Urol*. <https://doi.org/10.1007/s00345-018-2320-9> (**Epub ahead of print Review**)
  32. Ghosh A, Oliver R, Way C et al (2017) Results of day-case ureterorenoscopy (DC-URS) for stone disease: prospective outcomes over 4.5 years. *World J Urol* 35(11):1757–1764
  33. Somani BK, Robertson A, Kata SG (2011) Decreasing the cost of flexible ureterorenoscopic procedures. *Urology* 78(3):528–530
  34. Somani BK, Desai M, Traxer O et al (2014) Stone-free rate (SFR): a new proposal for defining levels of SFR. *Urolithiasis* 42(2):95
  35. Ishii H, Couzins M, Aboumarzouk O et al (2016) Outcomes of systematic literature review of ureteroscopy for stone disease in the obese and morbidly obese population. *J Endourol* 30(2):135–145
  36. Ishii H, Aboumarzouk O, Somani BK (2014) Current status of ureteroscopy for stone disease in pregnancy. *Urolithiasis* 42(1):1–7
  37. Jones P, Rob S, Griffin S et al (2019) Outcomes of ureteroscopy (URS) for stone disease in the paediatric population: results of over 100 URS procedures from a UK tertiary centre. *WJU*. <https://doi.org/10.1007/s00345-019-02745-3> (**Epub ahead of print**)
  38. Veneziano D, Ploumidis A, Proietti S et al (2019) Validation of the endoscopic stone treatment step 1 (EST-s1): a novel EAU training and assessment tool for basic endoscopic stone treatment skills—a collaborative work by ESU, ESUT and EULIS. *WJU* 11:78. <https://doi.org/10.1007/s00345-019-02736-4> (**Epub ahead of print**)
  39. Ridyard D, Dargosa L, Pais VM Jr (2016) From novelty to the every-day: the evolution of ureteroscopy. *Minerva Urol Nefrol* 68(6):469–478 (**Epub 2016 Sep 1. Review**)
  40. Kronenberg P, Somani B (2018) Advances in lasers for the treatment of stones—a systematic review. *Curr Urol Rep* 19(6):45. <https://doi.org/10.1007/s11934-018-0807-y>

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.